Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
5.24
-0.48 (-8.39%)
Apr 29, 2026, 10:10 AM EDT - Market open
Akari Therapeutics, Stock Forecast
AKTX's stock price has decreased by -89.61% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Akari Therapeutics, stock have an average target of 33.5, with a low estimate of 27 and a high estimate of 40. The average target predicts an increase of 539.31% from the current stock price of 5.24.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Akari Therapeutics, stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 8, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $1.6 → $27 | Strong Buy | Maintains | $1.6 → $27 | +415.27% | Apr 1, 2026 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +663.36% | Jan 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $64 | Strong Buy | Reiterates | $64 | +1,121.37% | Sep 9, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $200 | Strong Buy | Initiates | $200 | +3,716.79% | Jul 18, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-5.92
from -20.55
EPS Next Year
-6.63
from -5.92
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -5.92 | -6.63 | |
| Low | -11.76 | -13.72 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.